产品名称 AC 220 dihydrochloride - Quizartinib dihydrochloride
产品货号 Axon 1696 CAS [1132827-21-4] MF C29H32N6O4S.2HClMW 633.59 Purity: 98% Soluble in DMSO Description A uniquely potent, selective and efficacious inhibitor of FMS-Like Tyrosine kinase-3 (FLT3) for the treatment of AML; Second-generation FLT3 inhibitor that is highly potent with low nanomolar potency both in vitro and in cellular assays, and has a highly focused and selective interaction pattern across the human protein kinome. References Certificates Categories Extra info PP Zarrinkar et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009, 114 (14), 2984-2992.   PH Wiernik. FLT3 inhibitors for the treatment of acute myeloid leukemia. Clin. Adv. Hematol. Oncol. 2010, 8(6), 429-444.   Q Chao et al. Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and (...). J. Med. Chem. 2009, 52(23), 7808-7816. Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology FLT3 RTK class III; EC 2.7.10.1 FLT3 inhibitor Chemical name 1-(5-tert-Butyl-isoxazol-3-yl)-3-{4-[7-(2-morpholin-4-yl-ethoxy)-benzo[d]imidazo[2,1-b]thiazol-2-yl]-phenyl}-urea dihydrochloride Parent CAS No. [950769-58-1] Order Size Unit Price Stock 5 mg €90.00 In Stock
产品价格 现货询价,电话:010-67529703
产品规格
产品品牌 axonmedchem
产品概述
产品详情

AC 220 dihydrochloride - Quizartinib dihydrochloride

Based on 52 publications in PubMed 10 10 52

Axon 1696

CAS [1132827-21-4]

MF C29H32N6O4S.2HCl
MW 633.59

  • Purity: 98%
  • Soluble in DMSO

AC 220 dihydrochloride

Description

A uniquely potent, selective and efficacious inhibitor of FMS-Like Tyrosine kinase-3 (FLT3) for the treatment of AML; Second-generation FLT3 inhibitor that is highly potent with low nanomolar potency both in vitro and in cellular assays, and has a highly focused and selective interaction pattern across the human protein kinome.
产品资料